Abera Bioscience (NGM:ABERA) - Stock Price, News & Analysis

ABERA Stock Overview

A platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally.

About the company

ABERA fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Risk Analysis

Has less than 1 year of cash runway

Earnings have declined by 29.6% per year over past 5 years

Makes less than USD$1m in revenue (SEK9M)

Does not have a meaningful market cap (SEK56M)

+ 1 more risk

Abera Bioscience AB Competitors

Lipigon Pharmaceuticals

OM:LPGO

SEK 20.8m

Dextech Medical

NGM:DEX

SEK 76.2m

Elicera Therapeutics

OM:ELIC

SEK 69.1m

Sprint Bioscience

OM:SPRINT

SEK 120.0m

Price History & Performance

Summary of all time highs, changes and price drops for Abera Bioscience
Historical stock prices
Current Share Price	SEK 3.85
52 Week High	SEK 7.50
52 Week Low	SEK 3.51
Beta	1.04
11 Month Change	-6.33%
3 Month Change	-7.00%
1 Year Change	-19.62%
33 Year Change	-78.13%
5 Year Change	n/a
Change since IPO	-65.16%

Recent updates

We're Not Very Worried About Abera Bioscience's (NGM:ABERA) Cash Burn Rate

Nov 03

We Think Abera Bioscience (NGM:ABERA) Can Afford To Drive Business Growth

Jul 21

Shareholder Returns

	ABERA	SE Biotechs	SE Market
7D	-3.3%	-1.1%	-1.8%
1Y	-19.6%	23.8%	15.5%

Return vs Industry: ABERA underperformed the Swedish Biotechs industry which returned 28.9% over the past year.

Return vs Market: ABERA underperformed the Swedish Market which returned 22.5% over the past year.

Price Volatility

Is ABERA's price volatile compared to industry and market?
ABERA volatility
ABERA Average Weekly Movement	7.4%
Biotechs Industry Average Movement	9.0%
Market Average Movement	5.4%
10% most volatile stocks in SE Market	11.2%
10% least volatile stocks in SE Market	3.2%

Stable Share Price: ABERA has not had significant price volatility in the past 3 months compared to the Swedish market.

Volatility Over Time: ABERA's weekly volatility has decreased from 12% to 7% over the past year.

About the Company

Founded	Employees	CEO	Website
2012	6	Maria Alriksson	aberabio.com

Abera Bioscience AB, a platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally. The company’s development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead vaccine candidate is a universal pneumococcal vaccine based on the platform BERA.

Abera Bioscience AB Fundamentals Summary

How do Abera Bioscience's earnings and revenue compare to its market cap?
ABERA fundamental statistics
Market cap	SEK 55.68m
Earnings (TTM)	-SEK 7.63m
Revenue (TTM)	SEK 9.26m

6.0x

P/S Ratio

-7.3x

P/E Ratio

Is ABERA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ABERA income statement (TTM)
Revenue	SEK 9.26m
Cost of Revenue	SEK 0
Gross Profit	SEK 9.26m
Other Expenses	SEK 16.88m
Earnings	-SEK 7.63m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Nov 13, 2024

Earnings per share (EPS)	-0.53
Gross Margin	100.00%
Net Profit Margin	-82.39%
Debt/Equity Ratio	0%

How did ABERA perform over the long term?

See historical performance and comparison